Lorraine Fitzpatrick from Radius Health: New Medication Looks to Advance Treatment of Osteoperosis

In an aging population, more people are being diagnosed with osteoporosis every day. A new medication is being developed to help treat this patient population more effectively.

Lorraine Fitzpatrick, MD, chief medical officer at Radius Health discussed a new medication which is being developed for the condition during the annual meeting of the Endocrine Society (ENDO 2016) in Boston, Massachusetts. FItzpatrick discussed the recently completed phase III trials for abaloparatide, their investigational drug awaiting FDA approval. She said that the studies looked at bone mineral density in a patient population of more than 2,500 women for more than 18 months.